Livagen (Bioregulator)

Research Overview

Livagen serves as a research tool for investigating liver-specific bioregulation and hepatic tissue function in laboratory settings. This synthetic peptide bioregulator belongs to the class of Khavinson short peptides, a family of defined-sequence regulatory peptides originally identified through research on tissue-specific regulatory mechanisms. Hepatic research also employs Glutathione for investigating liver-specific antioxidant defense and detoxification pathways, and Ovagen as a complementary gastric-hepatic bioregulator. The short-peptide bioregulator concept proposes that defined peptide sequences act as information molecules that can influence cellular function in corresponding target tissues.

Livagen research applications extend across multiple areas of hepatic biology including hepatocyte metabolic function, detoxification enzyme regulation, bile production mechanisms, hepatic regeneration, and liver aging processes. Laboratory protocols examine these effects in cell culture systems, liver tissue explants, and preclinical animal models to understand hepatic tissue regulation at molecular and cellular levels.

The peptide’s liver-directed regulatory profile provides research interest in tissue selectivity and targeted cellular regulation. Studies investigate how short bioregulator peptides interact with hepatocytes, the mechanisms underlying tissue-specific effects, and potential applications in understanding liver function and hepatic system biology. Research models include primary hepatocyte cultures, hepatic cell lines, and various liver function assessment protocols.

Molecular Characteristics

Defined Composition:

• Classification: Synthetic peptide bioregulator (Khavinson short peptide)
• Source/Origin: Synthetic (solid-phase peptide synthesis)
• Amino Acid Sequence: Lys-Glu-Asp-Ala (KEDA)
• Molecular Formula: C₁₈H₃₁N₅O₉
• Molecular Weight: 461.47 Da
• Form: White to off-white lyophilized powder
• Solubility: Water, phosphate buffered saline, cell culture media

Livagen is a single, chemically defined tetrapeptide rather than a complex preparation. The molecule consists of the sequence Lys-Glu-Asp-Ala (KEDA), assembled by solid-phase peptide synthesis to a defined structure with consistent batch-to-batch identity. This defined composition reflects the short-peptide bioregulator methodology, where specific sequences are synthesized to a high degree of purity while preserving the biological activity profile studied in research models.

As a tetrapeptide with a molecular weight of 461.47 Da, Livagen exemplifies the short-chain regulatory peptides theorized to serve as information molecules, carrying tissue-specific regulatory signals that may influence gene expression and cellular function in target tissues. Its compact, defined sequence allows mechanistic studies to attribute observed effects to a single molecular entity.

Bioregulator Peptide Research Background

Livagen belongs to the research category of short peptide bioregulators developed to investigate tissue-specific cellular regulation. This research approach emerged from studies on how peptide signals influence cellular differentiation, function, and tissue homeostasis. The short-peptide bioregulator hypothesis proposes that:

1. Organs are associated with specific peptide signals that regulate cellular function
2. Defined short-peptide sequences demonstrate selective affinity for corresponding organs
3. These peptides may influence gene expression and protein synthesis in target cells
4. Bioregulator effects occur through interaction with cellular regulatory mechanisms

Research on liver bioregulators like Livagen investigates these mechanisms in hepatic tissue contexts, examining how peptide signals might modulate hepatocyte function, metabolic processes, and liver tissue homeostasis in experimental models.

Research Applications

Hepatocyte Function Research

Livagen serves as a research tool for investigating liver cell function and regulation:

• Metabolic Function Studies: Investigation of glucose metabolism, glycogen storage, gluconeogenesis, and energy homeostasis
• Gene Expression Research: Studies on liver-specific gene expression including metabolic enzymes, transport proteins, and regulatory factors
• Protein Synthesis Regulation: Examination of hepatic protein production including albumin, clotting factors, and transport proteins
• Cell Viability Studies: Research on hepatocyte survival, proliferation, and resistance to cellular stress
• Hepatocyte Phenotype Maintenance: Investigation of differentiated function stability in culture systems

Laboratory protocols employ primary hepatocyte cultures (human, rat, mouse), hepatocyte cell lines (HepG2, HepaRG, Huh7), and 3D culture systems to characterize Livagen effects on hepatocyte function.

Hepatic Metabolism Research

Research applications extend to liver metabolic pathway regulation:

• Phase I Metabolism Studies: Investigation of cytochrome P450 enzyme expression and activity
• Phase II Conjugation Research: Examination of glucuronidation, sulfation, and glutathione conjugation pathways
• Lipid Metabolism Studies: Research on fatty acid oxidation, lipogenesis, and cholesterol synthesis
• Amino Acid Metabolism: Investigation of transamination, urea cycle function, and protein metabolism
• Carbohydrate Metabolism: Studies on glycolysis, gluconeogenesis, and glycogen metabolism regulation

Experimental approaches include enzyme activity assays, metabolic flux analysis, and gene expression profiling to understand hepatic metabolic regulation.

Detoxification Pathway Research

Laboratory studies investigate Livagen in hepatic detoxification contexts:

• Xenobiotic Metabolism: Research on drug and toxin metabolism pathways
• Antioxidant System Studies: Examination of glutathione synthesis, superoxide dismutase, catalase expression
• Oxidative Stress Response: Investigation of Nrf2 pathway activation and antioxidant response elements
• Metal Detoxification: Research on metallothionein expression and heavy metal processing
• Bile Acid Metabolism: Studies on bile acid synthesis, conjugation, and transport

Research protocols examine how short bioregulator peptides might influence detoxification enzyme expression, antioxidant capacity, and protective mechanisms in hepatocyte models.

Hepatic Regeneration Studies

Livagen research applications include liver tissue renewal investigation:

• Hepatocyte Proliferation: Research on cell cycle re-entry and mitogenic signaling in normally quiescent hepatocytes
• Growth Factor Signaling: Investigation of HGF, EGF, and TGF-α signaling pathways
• Progenitor Cell Research: Studies on hepatic progenitor/stem cell activation and differentiation
• Tissue Remodeling: Examination of extracellular matrix changes during liver regeneration
• Regenerative Capacity: Investigation of compensatory growth mechanisms and tissue repair

Experimental models include partial hepatectomy models, injury-regeneration studies, and proliferation assays in hepatocyte cultures.

Hepatic Aging Research

Livagen serves as a tool for investigating age-related changes in liver tissue:

• Cellular Senescence Studies: Examination of aging markers in hepatocytes and non-parenchymal liver cells
• Telomere Research: Investigation of telomere dynamics in hepatic cells
• Metabolic Function Decline: Studies on age-related changes in hepatic metabolic capacity
• Regenerative Capacity Changes: Research on declining liver regeneration ability with aging
• Oxidative Damage Accumulation: Analysis of reactive oxygen species and oxidative modifications in aging liver

Research protocols employ aging models, senescence-associated marker analysis, and comparative studies across different age groups in experimental systems.

Hepatic Inflammation and Fibrosis Research

Laboratory studies examine Livagen effects on liver pathology models:

• Inflammatory Response Research: Investigation of cytokine production, NF-κB signaling, and inflammatory pathways
• Hepatic Stellate Cell Studies: Research on stellate cell activation, transdifferentiation, and collagen production
• Fibrosis Development: Examination of extracellular matrix deposition and tissue remodeling
• Kupffer Cell Function: Studies on resident macrophage activation and inflammatory mediator release
• Anti-fibrotic Mechanisms: Investigation of MMP/TIMP balance and matrix degradation pathways

Research approaches include co-culture models, inflammatory stimulus responses, and fibrosis marker analysis.

Laboratory Handling and Storage Protocols

Lyophilized Powder Storage:

• Store at 2-8°C (refrigerated) in original sealed vial
• Protect from light exposure and moisture
• Do not freeze lyophilized powder
• Stable for 24 months refrigerated as unopened vial
• Record receipt date for laboratory inventory

Handling Precautions:
Short peptide bioregulator preparations require careful handling to maintain activity:

• Use sterile technique for cell culture applications
• Avoid prolonged exposure to room temperature
• Minimize exposure to direct light
• Use appropriate peptide-compatible labware (low-binding tubes)
• Follow standard laboratory peptide handling protocols

Quality Assurance and Analytical Testing

Each Livagen batch undergoes characterization appropriate for a defined synthetic peptide:

Identity and Purity Analysis:

• High-Performance Liquid Chromatography (HPLC): Purity ≥98% by reversed-phase HPLC
• Mass spectrometry: Identity confirmed by ESI-MS, observed molecular weight 461.47 Da
• Amino acid analysis: Confirms Lys-Glu-Asp-Ala composition
• Peptide content determination: Quantifies net peptide content by weight

Purity Testing:

• Chromatographic purity: Single principal peak ≥98% by HPLC peak-area
• Related substances: Synthesis-related impurities below specified limits
• Counterion/residual content: Within specified limits
• Heavy metals: Below detection limits per pharmacopeia standards

Contaminant Testing:

• Bacterial endotoxin: <10 EU/mg (LAL method)
• Sterility testing: Sterile filtration and microbiological testing
• Residual solvents: Within acceptable limits
• Water content: Karl Fischer titration (<8%)

Identity Confirmation:

• Sequence verification: Lys-Glu-Asp-Ala (KEDA) confirmed analytically
• Mass confirmation: ESI-MS consistent with 461.47 Da
• Synthesis validation: Standardized solid-phase synthesis and purification protocols
• Batch-to-batch consistency: Quality control testing across production batches

Documentation:

• Certificate of Analysis (COA) with batch-specific data
• HPLC purity chromatogram
• Mass spectrometry identity report
• Quality control test results
• Storage and handling recommendations
• Lot number traceability

Research Considerations

Experimental Design Factors:

Researchers should consider several factors when designing experiments with Livagen:

1. Concentration Selection: Short peptide bioregulator research typically employs concentrations ranging from 0.1-10 μg/mL in cell culture studies. Optimal concentration should be determined empirically for specific experimental systems.

2. Treatment Duration: Published research suggests effects may require 24-72 hours to manifest in cell culture models. Longer durations may be needed for metabolic enzyme induction studies.

3. Cell Type Specificity: While designated as liver-directed, tissue selectivity should be verified in each experimental system through comparative studies with other cell types.

4. Hepatocyte Culture Challenges: Primary hepatocytes rapidly lose differentiated function in culture. Consider sandwich culture or 3D systems for extended studies.

5. Defined Sequence Advantage: As a single, chemically defined tetrapeptide, observed effects can be attributed to one molecular entity, simplifying mechanism studies relative to undefined preparations.

Control Groups:

Appropriate controls for short peptide bioregulator research include:

• Vehicle control (vehicle buffer only)
• Non-specific peptide control (scrambled peptides or unrelated bioregulator)
• Positive controls where applicable (growth factors, enzyme inducers)
• Tissue-specific comparisons (same bioregulator concentration in non-hepatic cells)

Mechanism Investigation:

Livagen mechanisms remain active research areas. Investigated mechanisms include:

• Gene expression modulation through transcription factor regulation (HNF4α, C/EBPs, PPARs)
• Epigenetic modifications influencing hepatic gene expression
• Nuclear receptor activation (PXR, CAR, FXR)
• Growth factor receptor signaling
• Metabolic pathway enzyme induction
• Direct nuclear effects on chromatin and gene regulation

Research approaches combine molecular biology techniques, genomic and proteomic analysis, metabolic assays, and functional liver tissue assessments to elucidate bioregulator action mechanisms.

Compliance and Safety Information

Regulatory Status:
Livagen is provided as a research chemical for in-vitro laboratory studies and preclinical research only. This synthetic peptide bioregulator has not been approved by the FDA for human therapeutic use, dietary supplementation, or medical applications.

Intended Use:

• In-vitro cell culture research
• Liver tissue explant studies
• In-vivo preclinical research in approved animal models
• Laboratory investigation of hepatic tissue regulation
• Academic and institutional research applications

NOT Intended For:

• Human consumption or administration
• Therapeutic treatment or diagnosis
• Dietary supplementation
• Veterinary therapeutic applications without appropriate oversight
• Any medical or clinical applications

Safety Protocols:
Researchers should follow standard laboratory safety practices:

• Use appropriate personal protective equipment (lab coat, gloves, safety glasses)
• Handle in biosafety cabinet for sterile work
• Follow institutional biosafety guidelines
• Dispose of waste according to laboratory waste protocols
• Consult material safety data sheet (MSDS) for additional information

Material Source Considerations:
Livagen is produced by chemical synthesis with no animal-derived starting materials. Researchers should:

• Follow institutional synthetic peptide handling guidelines
• Reference the Certificate of Analysis for identity and purity documentation
• Maintain records of batch-specific synthesis certification
• Apply appropriate biosafety level for synthetic research materials

—